×
About 18,000 results

ALLMedicine™ Ankylosing Spondylitis Center

Research & Reviews  7,543 results

Ankylosing spondylitis coexists with rheumatoid arthritis and Sjögren's syndrome: a cas...
https://doi.org/10.1007/s10067-020-05350-7
Clinical Rheumatology; Zhao GW, Huang LF et. al.

Sep 16th, 2020 - Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and Sjögren's syndrome (SS) are the most common rheumatic diseases. However, a coexistence of AS and RA or SS in the same patient is rare. What' s more, the case of AS coexists with RA, and S...

The effect of intravenous golimumab on health-related quality of life and work producti...
https://doi.org/10.1007/s10067-020-05342-7
Clinical Rheumatology; Reveille JD, Hwang MC et. al.

Sep 14th, 2020 - The effect of intravenous (IV) golimumab on health-related quality of life (HRQoL) and productivity in patients with ankylosing spondylitis (AS) was evaluated. Patients were randomized to IV golimumab 2 mg/kg (n = 105) at weeks 0, 4, then every 8 ...

Erosive costo-vertebral joint arthrits-an uncommon manifestation of ankylosing spondyli...
https://doi.org/10.1002/art.41514
Arthritis & Rheumatology (Hoboken, N.J.); Gazitt T, Nassrallah N et. al.

Sep 10th, 2020 - The patient, a 26-year old woman diagnosed with HLA-B27-associated ankylosing spondylitis (AS) currently not on therapy complained of new-onset mid-back pain. The pain was particularly noticeable during inspiration and yawning. Point tenderness at...

Cervical spine involvement in ankylosing spondylitis mimicking Eagle's syndrome.
https://doi.org/10.1093/rheumatology/keaa552
Rheumatology (Oxford, England); Uslu S

Sep 9th, 2020 - Cervical spine involvement in ankylosing spondylitis mimicking Eagle's syndrome.|2020|Uslu S,|

Relationship between common carotid distensibility/aortic stiffness and cardiac left ve...
https://www.ncbi.nlm.nih.gov/pubmed/32896250
Clinical and Experimental Rheumatology; Dalbeni A, Giollo A et. al.

Sep 8th, 2020 - Chronic inflammatory arthritis (CIAs), including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are characterised by high cardiovascular disease (CVD) risk, partly due to endothelial dysfunction and increased ...

see more →

Guidelines  37 results

2019 Update of the American College of Rheumatology/ Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis ...
https://www.rheumatology.org/Portals/0/Files/AxialSpA-Guideline-2019.pdf
Ward MM,et al

Sep 30th, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). ankylosing spondylitis

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.) References; Ward MM, Deodhar A et. al.

Aug 22nd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
https://www.businesswire.com/news/home/20190723006033/en/FDA-Approves-Samsung-Bioepis-HADLIMA%E2%84%A2-adalimumab-bwwd

Jul 23rd, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® i (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthr...

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States
http://www.samsungbioepis.com/en/newsroom/detail/FDA-Approves-ETICOVO-Samsung-Bioepis-Second-Anti-TNF-Medicine.html

Apr 28th, 2019 - Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthri...

2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guidelin...
https://www.rheumatology.org/Portals/0/Files/ACR-AAHKS-Perioperative-Management-Guideline.pdf
Goodman, S.,et al

Jul 31st, 2017 - This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence-based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid a.

see more →

Drugs  1,003 results see all →

Clinicaltrials.gov  8,819 results

Ankylosing spondylitis coexists with rheumatoid arthritis and Sjögren's syndrome: a cas...
https://doi.org/10.1007/s10067-020-05350-7
Clinical Rheumatology; Zhao GW, Huang LF et. al.

Sep 16th, 2020 - Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and Sjögren's syndrome (SS) are the most common rheumatic diseases. However, a coexistence of AS and RA or SS in the same patient is rare. What' s more, the case of AS coexists with RA, and S...

The effect of intravenous golimumab on health-related quality of life and work producti...
https://doi.org/10.1007/s10067-020-05342-7
Clinical Rheumatology; Reveille JD, Hwang MC et. al.

Sep 14th, 2020 - The effect of intravenous (IV) golimumab on health-related quality of life (HRQoL) and productivity in patients with ankylosing spondylitis (AS) was evaluated. Patients were randomized to IV golimumab 2 mg/kg (n = 105) at weeks 0, 4, then every 8 ...

Erosive costo-vertebral joint arthrits-an uncommon manifestation of ankylosing spondyli...
https://doi.org/10.1002/art.41514
Arthritis & Rheumatology (Hoboken, N.J.); Gazitt T, Nassrallah N et. al.

Sep 10th, 2020 - The patient, a 26-year old woman diagnosed with HLA-B27-associated ankylosing spondylitis (AS) currently not on therapy complained of new-onset mid-back pain. The pain was particularly noticeable during inspiration and yawning. Point tenderness at...

Cervical spine involvement in ankylosing spondylitis mimicking Eagle's syndrome.
https://doi.org/10.1093/rheumatology/keaa552
Rheumatology (Oxford, England); Uslu S

Sep 9th, 2020 - Cervical spine involvement in ankylosing spondylitis mimicking Eagle's syndrome.|2020|Uslu S,|

Naproxen - naproxen tablet-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ada35c9d-a491-fd4d-e053-2995a90a5349

Sep 8th, 2020 - Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium ta...

see more →

News  547 results

UK's Izana Bioscience tests rheumatoid arthritis drug in COVID-19 patients
https://www.reuters.com/article/us-health-coronavirus-therapy-izana/uks-izana-bioscience-tests-rheumatoid-arthritis-drug-in-covid-19-patients-idUSKBN21N0Z9

Apr 5th, 2020 - LONDON (Reuters) - UK-based biopharma company Izana Bioscience said it was testing its antibody therapy namilumab for the treatment of patients with rapidly worsening COVID-19 at the Humanitas Research Hospitals in Bergamo and Milan in Italy. Nami...

TNFi treatment shows hint of slowing axial spondyloarthritis radiographic progression
https://www.mdedge.com/rheumatology/article/215946/ankylosing-spondylitis/tnfi-treatment-shows-hint-slowing-axial?channel=299
Jeff Evans

Jan 22nd, 2020 - Tumor necrosis factor inhibitors may slow radiographic progression in the spine of patients with ankylosing spondylitis after at least 4 years of use, according to an analysis of studies with low risk of bias, but no evidence exists for slowed dis.

FDA approves infliximab-axxq for numerous indications
https://www.mdedge.com/familymedicine/article/213759/rheumatoid-arthritis/fda-approves-infliximab-axxq-numerous-indications?channel=39313
MDedge Rheumatology; Christopher Palmer

Dec 6th, 2019 - The Food and Drug Administration has approved the biosimilar infliximab-axxq (Avsola) for various indications, making it the fourth biosimilar of infliximab (Remicade) to be cleared for marketing by the agency. Wikimedia Commons/FitzColinGerald/ C.

see more →

Patient Education  51 results see all →